Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/93676
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Health Technology and Informatics | en_US |
dc.contributor | Department of Biomedical Engineering | en_US |
dc.contributor | Department of Health Technology and Informatics | - |
dc.contributor | Department of Biomedical Engineering | - |
dc.contributor | Research Institute for Future Food | - |
dc.creator | Gedefaw, L | en_US |
dc.creator | Ullah, S | en_US |
dc.creator | Lee, TMH | en_US |
dc.creator | Yip, SP | en_US |
dc.creator | Huang, CL | en_US |
dc.date.accessioned | 2022-07-25T02:42:44Z | - |
dc.date.available | 2022-07-25T02:42:44Z | - |
dc.identifier.issn | 2227-9059 | en_US |
dc.identifier.uri | http://hdl.handle.net/10397/93676 | - |
dc.language.iso | en | en_US |
dc.publisher | MDPI AG | en_US |
dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license https://creativecommons.org/licenses/by/4.0/). | en_US |
dc.rights | The following publication Gedefaw, L., Ullah, S., Lee, T. M., Yip, S. P., & Huang, C. L. (2021). Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. Biomedicines, 9(12), 1823 is available at https://doi.org/10.3390/biomedicines9121823 | en_US |
dc.subject | Inflammasome | en_US |
dc.subject | RNA interference | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Non-coding RNAs | en_US |
dc.subject | Molecular targets | en_US |
dc.title | Targeting inflammasome activation in COVID-19 : delivery of RNA interference-based therapeutic molecules | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.doi | 10.3390/biomedicines9121823 | en_US |
dcterms.abstract | Mortality and morbidity associated with COVID-19 continue to be significantly high worldwide, owing to the absence of effective treatment strategies. The emergence of different variants of SARS-CoV-2 is also a considerable source of concern and has led to challenges in the development of better prevention and treatment strategies, including vaccines. Immune dysregulation due to pro-inflammatory mediators has worsened the situation in COVID-19 patients. Inflammasomes play a critical role in modulating pro-inflammatory cytokines in the pathogenesis of COVID-19 and their activation is associated with poor clinical outcomes. Numerous preclinical and clinical trials for COVID-19 treatment using different approaches are currently underway. Targeting different inflammasomes to reduce the cytokine storm, and its associated complications, in COVID-19 patients is a new area of research. Non-coding RNAs, targeting inflammasome activation, may serve as an effective treatment strategy. However, the efficacy of these therapeutic agents is highly dependent on the delivery system. MicroRNAs and long non-coding RNAs, in conjunction with an efficient delivery vehicle, present a potential strategy for regulating NLRP3 activity through various RNA interference (RNAi) mechanisms. In this regard, the use of nanomaterials and other vehicle types for the delivery of RNAi-based therapeutic molecules for COVID-19 may serve as a novel approach for enhancing drug efficacy. The present review briefly summarizes immune dysregulation and its consequences, the roles of different non-coding RNAs in regulating the NLRP3 inflammasome, distinct types of vectors for their delivery, and potential therapeutic targets of microRNA for treatment of COVID-19. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Biomedicines, Dec. 2021, v. 9, no.12, 1823 | en_US |
dcterms.isPartOf | Biomedicines | en_US |
dcterms.issued | 2021-12 | - |
dc.identifier.isi | WOS:000736234400001 | - |
dc.identifier.scopus | 2-s2.0-85120536614 | - |
dc.identifier.pmid | 34944639 | - |
dc.identifier.artn | 1823 | en_US |
dc.description.validate | 202207 bcvc | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | HTI-0163 | - |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | Departmental seed fund from the Department of Health Technology and Informatics; Health and Medical Research Fund (no. COVID190208 to S.P.Y.) | en_US |
dc.description.pubStatus | Published | en_US |
dc.identifier.OPUS | 59152152 | - |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-09-01823.pdf | 2.29 MB | Adobe PDF | View/Open |
Page views
62
Last Week
1
1
Last month
Citations as of May 19, 2024
Downloads
20
Citations as of May 19, 2024
SCOPUSTM
Citations
7
Citations as of May 16, 2024
WEB OF SCIENCETM
Citations
6
Citations as of May 16, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.